Holen Sie sich die Stockscreener-App
0.602
4.14%
-0.026
Schlusskurs vom Vortag:
$0.628
Offen:
$0.6192
24-Stunden-Volumen:
180.17K
Relative Volume:
0.53
Marktkapitalisierung:
$38.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.37M
KGV:
-0.7818
EPS:
-0.77
Netto-Cashflow:
$-23.22M
1W Leistung:
+7.48%
1M Leistung:
-33.11%
6M Leistung:
-54.05%
1J Leistung:
-75.73%
1-Tages-Spanne:
$0.5911
$0.63
1-Wochen-Bereich:
$0.55
$0.6499
52-Wochen-Spanne:
$0.5402
$3.23
Cel-Sci Corp. Stock (CVM) Company Profile
Firmenname
Cel-Sci Corp.
Sektor
Branche
Telefon
703-506-9460
Adresse
8229 Boone Boulevard, Suite 802, Vienna, VA
Vergleichen Sie CVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CVM | 0.602 | 38.28M | 0 | -32.37M | -23.22M | -0.77 |
| VRTX | 450.44 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.80 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.35 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.78 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-02 | Eingeleitet | Dawson James | Buy |
Cel-Sci Corp. Aktie (CVM) Neueste Nachrichten
StockNews.com Upgrades CEL-SCI (NYSE:CVM) to “Hold” - Defense World
CVM stock touches 52-week low at $0.68 amid sharp annual decline - Investing.com India
CEL-SCI, FDA agree on Multikine trial design (CVM:NYSE) - Seeking Alpha
FDA agrees with CEL-SCI's patient selection for cancer study - Investing.com
3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference - Investing.com
3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference - Investing.com
CEL-SCI (FRA:LSRM) Free Cash Flow : €-17.72 Mil (TTM As of Jun. 2024) - GuruFocus.com
CVM stock touches 52-week low at $0.87 amid market challenges - Investing.com Australia
CVM stock touches 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
FDA panel challenges PD-L1 inhibitors, CEL-SCI's Multikine shows promise - Investing.com
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients - Yahoo Finance
Conestoga Capital Advisors Sold National Research Corp. (NRC), as it Fell Short of Expectations - Yahoo Finance UK
CVM stock touches 52-week low at $0.93 amid market challenges - Investing.com India
Exploring Opportunities in the Therapeutic Vaccines Market: - openPR
CVM stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CEL-SCI (NYSE:CVM) Trading Down 3.8%Here's What Happened - MarketBeat
SEC Form POS AM filed by Cel-Sci Corporation - Quantisnow
A company insider recently sold 10,000 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine - Business Wire
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer - Yahoo Finance
Annaly Capital Management Inc [NLY] CEO and CIO makes an insider purchase of 50,000 shares worth 1.0 million. - Knox Daily
CVM Stock Sees Decline of Approximately -6.25% in Last Five Days - Knox Daily
How to interpret Cel-Sci Corp. (CVM)’s stock chart patterns - US Post News
Cel-Sci Corp.’s Market Journey: Closing Weak at 1.05, Down -1.87 - The Dwinnex
Healthcare Stock Performance - Yahoo Finance
CEL-SCI Co. (NYSE:CVM) Position Raised by Thoroughbred Financial Services LLC - Defense World
Celonis expands alliance with Samsung for process optimisation - Yahoo! Voices
Stifel Upgrades Celestica Inc. (CLS) to Buy from Hold - Insider Monkey
Creo Sells Stake of Subsidiary to Chinese Market-Leader - Business News Wales
Celonis Expands Partnership with Samsung Fire & Marine Insurance to Optimize Processes and to Drive Value - Business Wire
Check out these key findings about Complete Solaria Inc. (CSLR) - SETE News
Trend Tracker for (CLS) - Stock Traders Daily
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Investing in Complete Solaria Inc. (CSLR) Is Getting More Attractive - Knox Daily
CVM’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Exact Sciences Debuts Positive Topline Results for Trial of Blood-Based Colorectal Cancer Screening Algorithm - Patient Care Online
Potential Price Increase for Cel-Sci Corp. (CVM) After Recent Insider Activity - Knox Daily
ESMO: Exact Sciences shows off early colorectal cancer blood test data - Fierce Biotech
Multikine shows promise in head and neck cancer study - Investing.com
Healthy Upside Potential: Celestica, Inc. (CLS) - SETE News
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial - Medical Device Network
CEL-SCI Corp's (CVM) Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - StreetInsider.com
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation – Company AnnouncementFT.com - Financial Times
Exact Sciences announces data for CRC screening test - TipRanks
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - Yahoo Finance
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 - Business Wire
Celestica Inc. (CLS): Among the Worst Performing AI Stocks of Previous Week - Insider Monkey
Finanzdaten der Cel-Sci Corp.-Aktie (CVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):